Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1517387 | 0.85 | S1PR1 (0.41) | S1PR1S1PR3PIM1EPHX1KDM4E | |
| Hydrochloric Acid SCHEMBL6656296 | 0.81 | S1PR1 (0.39) | S1PR1S1PR3SSTR3PIM1EPHX1 | |
| SCHEMBL6659778 | 0.80 | SIGMAR1 (0.30) | — | |
| SCHEMBL19367684 | 0.80 | SIGMAR1 (0.30) | — | |
| SCHEMBL22210750 | 0.78 | SIGMAR1 (0.33) | EPHX1ALDH1A1 | |
| SCHEMBL26620784 | 0.77 | S1PR1 (0.37) | S1PR1S1PR3PIM1EPHX1KDM4E | |
| Hydrochloric Acid SCHEMBL6663231 | 0.75 | — | — | |
| Perchlorate SCHEMBL6664783 | 0.75 | S1PR1 (0.36) | S1PR1S1PR3PIM1EPHX1KDM4E | |
| SCHEMBL24317842 | 0.73 | KDM4E (0.36) | S1PR1S1PR3PIM1EPHX1KDM4E | |
| SCHEMBL21660010 | 0.72 | SMN1; SMN2 (0.40) | S1PR1S1PR3EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | S1PR1 120/4885S1PR3 97/4885SSTR3 361/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | S1PR1 120/4885S1PR3 97/4885SSTR3 361/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | S1PR1 130/4885S1PR3 97/4885SSTR3 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.